(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Record-breaking 'space laser' erupts from merging galaxies 8 billion light-years away - 2They relied on marijuana to get through the day. But then days felt impossible without it
- 3From Iran to Israel: An Iranian volunteer’s unlikely stand in wartime
- 4Will your baby get a hep B vaccine? What RFK panel's ruling means.
- 5The Way to Business: Startup Illustrations Learned
- Individual Preparation Administrations to Raise Your Wellness Process
- Parents who delay baby's first vaccines also likely to skip measles shots
- NASA begins the countdown for humanity's first launch to the moon in 53 years
- Key Caper d: A Survey of \Procedure and Tomfoolery Released\ Tabletop game
- My skin feels drier, my lips thinner and my makeup heavier. How do I adjust my routine for aging skin?
- Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool
- Israel approves 19 new West Bank settlements in major annexation push
- 5 Great and High Evaluated Scene Configuration Administrations For 2024
- Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
